Controlled release of matrix metalloproteinase 1 with or without skeletal myoblasts transplantation improves cardiac function of rat hearts with chronic myocardial infarction

Tissue Eng Part A. 2009 Sep;15(9):2699-706. doi: 10.1089/ten.TEA.2008.0637.


Skeletal myoblast transplantation has been applied clinically for severe ischemic cardiomyopathy. Matrix metalloproteinase 1 (MMP-1) reduces fibrosis and prevents the progress of heart failure. We hypothesized that MMP-1 administration to the infarct area enhances the efficacy of skeletal myoblast transplantation. The controlled release of MMP-1 improved cardiac functions of rats with chronic myocardiac infarction with or without transplantation of skeletal myoblasts. Improvement in cardiac function and small fibrotic area inside the infarcted area were observed compared with those of myoblast transplantation. In conclusion, controlled release of MMP-1 was effective in cardioprotection in postmyocardial infarction although the combination with cell transplantation showed the similar effect.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cardiac Catheterization
  • Chronic Disease
  • DNA / administration & dosage
  • Delayed-Action Preparations
  • Fibrosis
  • Fluorescent Antibody Technique
  • Heart Function Tests*
  • Humans
  • Matrix Metalloproteinase 1 / administration & dosage*
  • Myoblasts, Skeletal / transplantation*
  • Myocardial Infarction / diagnostic imaging
  • Myocardial Infarction / pathology
  • Myocardial Infarction / physiopathology*
  • Myocardial Infarction / therapy*
  • Myocardium / pathology
  • Organ Size
  • Plasmids / administration & dosage
  • Rats
  • Rats, Inbred Lew
  • Tissue Donors
  • Ultrasonography


  • Delayed-Action Preparations
  • DNA
  • Matrix Metalloproteinase 1